pulldown Search Results


94
Cytoskeleton Inc glutathione sepharose
Glutathione Sepharose, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glutathione sepharose/product/Cytoskeleton Inc
Average 94 stars, based on 1 article reviews
glutathione sepharose - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

95
Cytoskeleton Inc activation assay biochem kit
Activation Assay Biochem Kit, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/activation assay biochem kit/product/Cytoskeleton Inc
Average 95 stars, based on 1 article reviews
activation assay biochem kit - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

96
Cytoskeleton Inc cdc42
Cdc42, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdc42/product/Cytoskeleton Inc
Average 96 stars, based on 1 article reviews
cdc42 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
Cytoskeleton Inc rhotekin rbd agarose beads
Rhotekin Rbd Agarose Beads, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhotekin rbd agarose beads/product/Cytoskeleton Inc
Average 96 stars, based on 1 article reviews
rhotekin rbd agarose beads - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
Cytoskeleton Inc bk035 piercetm bca protein assay kit thermo scientifictm
Bk035 Piercetm Bca Protein Assay Kit Thermo Scientifictm, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bk035 piercetm bca protein assay kit thermo scientifictm/product/Cytoskeleton Inc
Average 96 stars, based on 1 article reviews
bk035 piercetm bca protein assay kit thermo scientifictm - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

95
Cytoskeleton Inc rac1 gtp pull down assays
Rac1 Gtp Pull Down Assays, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rac1 gtp pull down assays/product/Cytoskeleton Inc
Average 95 stars, based on 1 article reviews
rac1 gtp pull down assays - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

93
Cytoskeleton Inc arf6 activation
Arf6 Activation, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/arf6 activation/product/Cytoskeleton Inc
Average 93 stars, based on 1 article reviews
arf6 activation - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

96
Thermo Fisher tag isolation
Tag Isolation, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tag isolation/product/Thermo Fisher
Average 96 stars, based on 1 article reviews
tag isolation - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

94
Cytoskeleton Inc rhoa rac1 cdc42 activation assay combo biochem kit
Increased activity of SGK1 promotes pinocytosis in Akt3−/− macrophages. A, phosphorylation of Akt (Ser-473/Thr-308), total Akt, and Akt1/2 expression in WT and Akt3−/− MPMs treated with 50 ng/ml M-CSF. Ctl, control without M-CSF treatment. n = 3. B, uptake of Lucifer yellow dye by WT and Akt3−/− MPMs in the presence of 10 μm GSK3 inhibitor (SB), 20 nm mTOR inhibitor (RAPA), or 2 μm NFκB inhibitor (BAY). n = 8. C, phosphorylation and expression of NDRG1, an SGK1 specific substrate, in WT and Akt3−/− MPMs assessed by Western blotting. Bottom panel, expression of SGK1 in WT and Akt3−/− MPMs. n = 3. D, Lucifer yellow uptake by MPMs in the presence of SGK1 inhibitor (K-650394). n = 8. E, foam cell formation assay in WT and Akt3−/− MPMs cultured in the presence of 1 mg/ml LDL and in the presence or absence of 25 μg/ml SGK1 inhibitor (SGK1i) for 24 h (n = 8). F, effect of SGK1 inhibitor (GSK-650394, 25 μg/ml) on the uptake of Lucifer yellow by WT and Akt3−/− MPMs (n = 7). G, effect of Akt3 siRNA treatment on phosphorylation of NDRG1 and expression of NDRG1, Akt3, and <t>Cdc42</t> in human MDMs assessed by Western blotting. GAPDH expression was used as a loading control (n = 6). H, uptake of Lucifer yellow dye by human MDM treated with control siRNA or Akt3 siRNA in the presence of 25 μg/ml SGK1i (n = 6). I, effect of 25 μg/ml SGKi on cholesterol accumulation in human MDM (n = 6). Human MDM were treated with Akt3 or control siRNA treatment and then cultured in the presence of 1 mg/ml LDL and 25 μg/ml SGK1i overnight, and cholesterol content was quantified. Data represent means ± S.E. *, p < 0.05. Data are representative of at least three independent experiments and are quantified from at least three independent experiments.
Rhoa Rac1 Cdc42 Activation Assay Combo Biochem Kit, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhoa rac1 cdc42 activation assay combo biochem kit/product/Cytoskeleton Inc
Average 94 stars, based on 1 article reviews
rhoa rac1 cdc42 activation assay combo biochem kit - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

92
Cytoskeleton Inc arf1 activation assay biochem kit
Increased activity of SGK1 promotes pinocytosis in Akt3−/− macrophages. A, phosphorylation of Akt (Ser-473/Thr-308), total Akt, and Akt1/2 expression in WT and Akt3−/− MPMs treated with 50 ng/ml M-CSF. Ctl, control without M-CSF treatment. n = 3. B, uptake of Lucifer yellow dye by WT and Akt3−/− MPMs in the presence of 10 μm GSK3 inhibitor (SB), 20 nm mTOR inhibitor (RAPA), or 2 μm NFκB inhibitor (BAY). n = 8. C, phosphorylation and expression of NDRG1, an SGK1 specific substrate, in WT and Akt3−/− MPMs assessed by Western blotting. Bottom panel, expression of SGK1 in WT and Akt3−/− MPMs. n = 3. D, Lucifer yellow uptake by MPMs in the presence of SGK1 inhibitor (K-650394). n = 8. E, foam cell formation assay in WT and Akt3−/− MPMs cultured in the presence of 1 mg/ml LDL and in the presence or absence of 25 μg/ml SGK1 inhibitor (SGK1i) for 24 h (n = 8). F, effect of SGK1 inhibitor (GSK-650394, 25 μg/ml) on the uptake of Lucifer yellow by WT and Akt3−/− MPMs (n = 7). G, effect of Akt3 siRNA treatment on phosphorylation of NDRG1 and expression of NDRG1, Akt3, and <t>Cdc42</t> in human MDMs assessed by Western blotting. GAPDH expression was used as a loading control (n = 6). H, uptake of Lucifer yellow dye by human MDM treated with control siRNA or Akt3 siRNA in the presence of 25 μg/ml SGK1i (n = 6). I, effect of 25 μg/ml SGKi on cholesterol accumulation in human MDM (n = 6). Human MDM were treated with Akt3 or control siRNA treatment and then cultured in the presence of 1 mg/ml LDL and 25 μg/ml SGK1i overnight, and cholesterol content was quantified. Data represent means ± S.E. *, p < 0.05. Data are representative of at least three independent experiments and are quantified from at least three independent experiments.
Arf1 Activation Assay Biochem Kit, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/arf1 activation assay biochem kit/product/Cytoskeleton Inc
Average 92 stars, based on 1 article reviews
arf1 activation assay biochem kit - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

Image Search Results


Increased activity of SGK1 promotes pinocytosis in Akt3−/− macrophages. A, phosphorylation of Akt (Ser-473/Thr-308), total Akt, and Akt1/2 expression in WT and Akt3−/− MPMs treated with 50 ng/ml M-CSF. Ctl, control without M-CSF treatment. n = 3. B, uptake of Lucifer yellow dye by WT and Akt3−/− MPMs in the presence of 10 μm GSK3 inhibitor (SB), 20 nm mTOR inhibitor (RAPA), or 2 μm NFκB inhibitor (BAY). n = 8. C, phosphorylation and expression of NDRG1, an SGK1 specific substrate, in WT and Akt3−/− MPMs assessed by Western blotting. Bottom panel, expression of SGK1 in WT and Akt3−/− MPMs. n = 3. D, Lucifer yellow uptake by MPMs in the presence of SGK1 inhibitor (K-650394). n = 8. E, foam cell formation assay in WT and Akt3−/− MPMs cultured in the presence of 1 mg/ml LDL and in the presence or absence of 25 μg/ml SGK1 inhibitor (SGK1i) for 24 h (n = 8). F, effect of SGK1 inhibitor (GSK-650394, 25 μg/ml) on the uptake of Lucifer yellow by WT and Akt3−/− MPMs (n = 7). G, effect of Akt3 siRNA treatment on phosphorylation of NDRG1 and expression of NDRG1, Akt3, and Cdc42 in human MDMs assessed by Western blotting. GAPDH expression was used as a loading control (n = 6). H, uptake of Lucifer yellow dye by human MDM treated with control siRNA or Akt3 siRNA in the presence of 25 μg/ml SGK1i (n = 6). I, effect of 25 μg/ml SGKi on cholesterol accumulation in human MDM (n = 6). Human MDM were treated with Akt3 or control siRNA treatment and then cultured in the presence of 1 mg/ml LDL and 25 μg/ml SGK1i overnight, and cholesterol content was quantified. Data represent means ± S.E. *, p < 0.05. Data are representative of at least three independent experiments and are quantified from at least three independent experiments.

Journal: The Journal of Biological Chemistry

Article Title: Akt3 kinase suppresses pinocytosis of low-density lipoprotein by macrophages via a novel WNK/SGK1/Cdc42 protein pathway

doi: 10.1074/jbc.M116.773739

Figure Lengend Snippet: Increased activity of SGK1 promotes pinocytosis in Akt3−/− macrophages. A, phosphorylation of Akt (Ser-473/Thr-308), total Akt, and Akt1/2 expression in WT and Akt3−/− MPMs treated with 50 ng/ml M-CSF. Ctl, control without M-CSF treatment. n = 3. B, uptake of Lucifer yellow dye by WT and Akt3−/− MPMs in the presence of 10 μm GSK3 inhibitor (SB), 20 nm mTOR inhibitor (RAPA), or 2 μm NFκB inhibitor (BAY). n = 8. C, phosphorylation and expression of NDRG1, an SGK1 specific substrate, in WT and Akt3−/− MPMs assessed by Western blotting. Bottom panel, expression of SGK1 in WT and Akt3−/− MPMs. n = 3. D, Lucifer yellow uptake by MPMs in the presence of SGK1 inhibitor (K-650394). n = 8. E, foam cell formation assay in WT and Akt3−/− MPMs cultured in the presence of 1 mg/ml LDL and in the presence or absence of 25 μg/ml SGK1 inhibitor (SGK1i) for 24 h (n = 8). F, effect of SGK1 inhibitor (GSK-650394, 25 μg/ml) on the uptake of Lucifer yellow by WT and Akt3−/− MPMs (n = 7). G, effect of Akt3 siRNA treatment on phosphorylation of NDRG1 and expression of NDRG1, Akt3, and Cdc42 in human MDMs assessed by Western blotting. GAPDH expression was used as a loading control (n = 6). H, uptake of Lucifer yellow dye by human MDM treated with control siRNA or Akt3 siRNA in the presence of 25 μg/ml SGK1i (n = 6). I, effect of 25 μg/ml SGKi on cholesterol accumulation in human MDM (n = 6). Human MDM were treated with Akt3 or control siRNA treatment and then cultured in the presence of 1 mg/ml LDL and 25 μg/ml SGK1i overnight, and cholesterol content was quantified. Data represent means ± S.E. *, p < 0.05. Data are representative of at least three independent experiments and are quantified from at least three independent experiments.

Article Snippet: Cdc42 activity in cell lysates was measured using a RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit (Cytoskeleton) ( n = 3).

Techniques: Activity Assay, Expressing, Control, Western Blot, Tube Formation Assay, Cell Culture

Akt3 inhibits macrophage pinocytosis via the SGK1/Cdc42 pathway. A, uptake of Lucifer yellow by WT and Akt3−/− MPMs in the presence or absence of 10 μm Cdc42 inhibitor (ML141). n = 8. B, uptake of Lucifer yellow dye by human MDMs treated with control siRNA or Akt3 siRNA in the presence of 10 μm ML141 (n = 6). C, cellular cholesterol levels of human MDMs treated with Akt3 siRNA or control siRNA in the presence of 1 mg/ml LDL and 10 μm ML141 (n = 6). D, Cdc42 activity in WT and Akt3−/− MPMs. Macrophages were treated with 25 μg/ml SGK1i overnight. Cells were then washed and lysed. Cdc42 activity in cell lysates was measured using a RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit (Cytoskeleton) (n = 3). E, expression of Cdc42 in WT and Akt3−/− MPMs cultured in the presence or absence of 25 μg/ml SGK1i or 1 mg/ml LDL (n = 3). F, effect of suppression of Akt3 expression (siRNA treatment for 48 h, Akt3i) on Cdc42 expression in human MDM as assessed by Western blot analysis. GAPDH expression was used as a loading control (n = 6). G, expression of Rac1 in macrophages treated with 25 μg/ml SGK1 inhibitor and 0.8 mg/ml LDL (top panel). (n = 3). H, effect of SGK1i on RhoA expression in WT and Akt3−/− MPMs. Cells were incubated with or without 25 μg/ml SGK1i overnight. Cell protein samples were assessed by Western blot analysis. I, F-actin formation in WT and Akt3−/− MPMs exposed to 500 μ/ml LDL in the presence or absence (control) of SGK1 inhibitor. Center panels, F-actin formation (white arrows) at higher magnification. The actin cytoskeleton and the nuclei were visualized by staining with Alexa Fluor 488-phalloidin and DAPI, respectively. Scale bars = 25 μm, n = 8. Right panels, quantification of phalloidin fluorescence intensity. J, macrophages treated with 500 μg/ml LDL in the presence or absence of 25 μg/ml SGK inhibitor (GSK650394) for 4 h. Cells were stained with 0.6 μm TRITC-phalloidin. TRITC-phalloidin·F-actin complexes were extracted, and fluorescence was measured by SPECTRAmax GEMINI XS. Data represent means ± S.E. *, p < 0.05. Data are representative of at least three independent experiments.

Journal: The Journal of Biological Chemistry

Article Title: Akt3 kinase suppresses pinocytosis of low-density lipoprotein by macrophages via a novel WNK/SGK1/Cdc42 protein pathway

doi: 10.1074/jbc.M116.773739

Figure Lengend Snippet: Akt3 inhibits macrophage pinocytosis via the SGK1/Cdc42 pathway. A, uptake of Lucifer yellow by WT and Akt3−/− MPMs in the presence or absence of 10 μm Cdc42 inhibitor (ML141). n = 8. B, uptake of Lucifer yellow dye by human MDMs treated with control siRNA or Akt3 siRNA in the presence of 10 μm ML141 (n = 6). C, cellular cholesterol levels of human MDMs treated with Akt3 siRNA or control siRNA in the presence of 1 mg/ml LDL and 10 μm ML141 (n = 6). D, Cdc42 activity in WT and Akt3−/− MPMs. Macrophages were treated with 25 μg/ml SGK1i overnight. Cells were then washed and lysed. Cdc42 activity in cell lysates was measured using a RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit (Cytoskeleton) (n = 3). E, expression of Cdc42 in WT and Akt3−/− MPMs cultured in the presence or absence of 25 μg/ml SGK1i or 1 mg/ml LDL (n = 3). F, effect of suppression of Akt3 expression (siRNA treatment for 48 h, Akt3i) on Cdc42 expression in human MDM as assessed by Western blot analysis. GAPDH expression was used as a loading control (n = 6). G, expression of Rac1 in macrophages treated with 25 μg/ml SGK1 inhibitor and 0.8 mg/ml LDL (top panel). (n = 3). H, effect of SGK1i on RhoA expression in WT and Akt3−/− MPMs. Cells were incubated with or without 25 μg/ml SGK1i overnight. Cell protein samples were assessed by Western blot analysis. I, F-actin formation in WT and Akt3−/− MPMs exposed to 500 μ/ml LDL in the presence or absence (control) of SGK1 inhibitor. Center panels, F-actin formation (white arrows) at higher magnification. The actin cytoskeleton and the nuclei were visualized by staining with Alexa Fluor 488-phalloidin and DAPI, respectively. Scale bars = 25 μm, n = 8. Right panels, quantification of phalloidin fluorescence intensity. J, macrophages treated with 500 μg/ml LDL in the presence or absence of 25 μg/ml SGK inhibitor (GSK650394) for 4 h. Cells were stained with 0.6 μm TRITC-phalloidin. TRITC-phalloidin·F-actin complexes were extracted, and fluorescence was measured by SPECTRAmax GEMINI XS. Data represent means ± S.E. *, p < 0.05. Data are representative of at least three independent experiments.

Article Snippet: Cdc42 activity in cell lysates was measured using a RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit (Cytoskeleton) ( n = 3).

Techniques: Control, Activity Assay, Activation Assay, Expressing, Cell Culture, Western Blot, Incubation, Staining, Fluorescence